(R)-3-(pyrrolidin-3-yloxy)pyridine | 259261-88-6

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: (R)-3-(pyrrolidin-3-yloxy)pyridine
• 英文别名: 3-(3-(R)-Pyrrolidinyloxy)-pyridine；(3R)-3-(pyridin-3-yloxy)pyrrolidine；3-[(3R)-pyrrolidin-3-yl]oxypyridine
• CAS: 259261-88-6
• 化学式: C₉H₁₂N₂O
• 分子量: 164.207
• InChiKey: DCWKRPJLVIHGCZ-SECBINFHSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.6
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.44
• 拓扑面积：
  34.2
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  (R)-3-(pyrrolidin-3-yloxy)pyridine 在 sodium hydroxide 、 NaCNBH3 、 三氟乙酸 、 paraformaldehyde 作用下， 以 四氢呋喃 为溶剂， 以9 mg (5%)的产率得到3-(1-methyl-3-(R)-pyrrolidinyloxy)-pyridine
  参考文献：
  名称：

  Pyridyl ethers and thioethers as ligands for nicotinic acetylcholine receptor and its therapeutic application

  摘要：

  本发明提供了以下式的化合物： 其中m为0、1或2；p为0或1；Y为O、S、S(O)或S(O)2；R1至R7为各种取代基，作为选择性调节尼古丁乙酰胆碱受体的药物，用于治疗疼痛、阿尔茨海默病、记忆丧失或痴呆症或运动功能丧失。

  公开号：

  US20030207858A1
• 作为产物：
  描述：

  (R)-3-(pyridin-3-yloxy)pyrrolidine-1-carboxylic acid tert-butyl ester 在 三氟乙酸 作用下， 以 二氯甲烷 为溶剂， 反应 16.0h， 以0.084 g的产率得到(R)-3-(pyrrolidin-3-yloxy)pyridine
  参考文献：
  名称：

  Discovery of a Series of 6,7-Dimethoxy-4-pyrrolidylquinazoline PDE10A Inhibitors

  摘要：

  A papaverine based pharmacophore model for PDE10A inhibition was generated via SBDD and used to design a library of 4-amino-6,7-dimethoxyquinazolines. From this library emerged an aryl ether pyrrolidyl 6,7-dimethoxyquinazoline series that became the focal point for additional modeling, X-ray, and synthetic efforts toward increasing PDE10A inhibitory potency and selectivity versus PDE3A/B. These efforts culminated in the discovery of 29, a potent and selective brain penetrable inhibitor of PDE10A.

  DOI：

  10.1021/jm060653b

文献信息

• [EN] BICYCLIC DERIVATIVES FOR USE IN THE TREATMENT OF ANDROGEN RECEPTOR ASSOCIATED CONDITIONS<br/>[FR] DÉRIVÉS BICYCLIQUES DESTINÉS À ÊTRE UTILISÉS DANS LE TRAITEMENT D'AFFECTIONS ASSOCIÉES AU RÉCEPTEUR DES ANDROGÈNES
  申请人：ASTRAZENECA AB

  公开号：WO2009081197A1

  公开（公告）日：2009-07-02

  The invention concerns bicyclic compounds of Formula (I), wherein the integers X1, X2, X3, Ring A, R4, R5 and m are as defined in the description. The present invention also relates to processes for the preparation of such compounds, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use in the prevention or treatment of androgen-receptor associated conditions.

  该发明涉及式(I)的双环化合物，其中整数X1、X2、X3、环A、R4、R5和m的定义如描述中所示。本发明还涉及制备这些化合物的方法、含有它们的药物组合物以及它们在制备用于预防或治疗雄激素受体相关疾病的药物中的应用。
• [EN] PYRIDYL ETHERS AND THIOETHERS AS LIGANDS FOR NICOTINIC ACETYLCHOLINE RECEPTOR AND ITS THERAPEUTIC APPLICATION<br/>[FR] PYRIDYL ETHERS ET THIOETHERS TENANT LIEU DE LIGANDS POUR LE RECEPTEUR DE L'ACETYCHOLINE NICOTINIQUE, ET APPLICATION THERAPEUTIQUE
  申请人：ORTHO MCNEIL PHARM INC

  公开号：WO2000010997A1

  公开（公告）日：2000-03-02

  The present invention provides compounds of formula (I) wherein m is 0, 1 or 2; p is 0 or 1; Y is O, S, S(O) or S(O)2 and R1 to R7 are various substituents as selective modulators of the nicotinic acetylcholine receptor useful in the treatment of pain, Alzheimer's disease, memory loss or dementia or loss of motor function.

  本发明提供了式（I）的化合物，其中m为0、1或2；p为0或1；Y为O、S、S（O）或S（O）2，R1至R7为不同的取代基，作为选择性调节剂，对尼古丁乙酰胆碱受体具有有用的治疗作用，可用于疼痛、阿尔茨海默病、记忆丧失或痴呆症或运动功能丧失的治疗。
• BICYCLIC DERIVATIVES FOR USE IN THE TREATMENT OF ANDROGEN RECEPTOR ASSOCIATED CONDITIONS-155
  申请人：Bradbury Robert Hugh

  公开号：US20100016279A1

  公开（公告）日：2010-01-21

  The invention concerns bicyclic compounds of Formula I wherein the integers X 1 , X 2 , X 3 , Ring A, R 4 , R 5 and m are as defined in the description. The present invention also relates to processes for the preparation of such compounds, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use in the prevention or treatment of androgen-receptor associated conditions.

  本发明涉及公式I的双环化合物，其中整数X1、X2、X3、环A、R4、R5和m如描述中所定义。本发明还涉及制备这种化合物的方法、包含它们的制药组合物以及它们在制造用于预防或治疗与雄激素受体相关疾病的药物中的应用。
• Bicyclic derivatives for use in the treatment of androgen receptor associated conditions-155
  申请人：AstraZeneca AB

  公开号：US08003649B2

  公开（公告）日：2011-08-23

  The invention concerns bicyclic compounds of Formula I wherein the integers X1, X2, X3, Ring A, R4, R5 and m are as defined in the description. The present invention also relates to processes for the preparation of such compounds, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use in the prevention or treatment of androgen-receptor associated conditions.

  本发明涉及式I的双环化合物，其中整数X1、X2、X3、环A、R4、R5和m的定义如描述中所述。本发明还涉及制备此类化合物的方法、含有它们的制药组合物以及它们在制造用于预防或治疗雄激素受体相关疾病的药物中的应用。
• PYRIDYL ETHERS AND THIOETHERS AS LIGANDS FOR NICOTINIC ACETYLCHOLINE RECEPTOR AND ITS THERAPEUTIC APPLICATION
  申请人：Ortho-McNeil Pharmaceutical, Inc.

  公开号：EP1107965B1

  公开（公告）日：2004-08-11